Cytisine / mual

Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

To review cytisine's history of use, pre-clinical evidence, clinical pharmacokinetics, efficacy, adverse reactions (ARs) and safety for smoking cessation.A synoptic review of the use of cytisine as a smoking cessation medication, mechanism of action,

An uncontrolled trial of cytisine (Tabex) for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

OBJECTIVE Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the alpha4beta2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine. There is insufficient

Cytisine versus nicotine for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Placebo-controlled trials indicate that cytisine, a partial agonist that binds the nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quitting at 6 months. We investigated whether cytisine was at least as effective as nicotine-replacement

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Tobacco smoking is one of the leading causes of deaths worldwide. Nearly one-fifth of adults in the UK regularly smoke cigarettes. The ill-health associated with smoking costs the NHS over £3B every year. A number of pharmacological interventions are available that can help people to quit

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). OBJECTIVE The primary objective of this

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine

Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Green tobacco sickness occurs from transdermal absorption of chemicals from freshly harvested, green tobacco leaves. Signs and symptoms include nausea, vomiting, headache, and abdominal cramps. Prevalence has shifted from the United States and Europe to China, India, and Brazil. Worldwide 8 million

Nicotine receptor partial agonists for smoking cessation.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). OBJECTIVE To review the efficacy of nicotine

cytisine/mual

Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.

An uncontrolled trial of cytisine (Tabex) for smoking cessation.

Cytisine versus nicotine for smoking cessation.

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.

Nicotine receptor partial agonists for smoking cessation.

Nicotine receptor partial agonists for smoking cessation.

Nicotine receptor partial agonists for smoking cessation.

Nicotine receptor partial agonists for smoking cessation.

Nicotine receptor partial agonists for smoking cessation.

Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.

Nicotine receptor partial agonists for smoking cessation.

Database tanaman obat terlengkap yang didukung oleh sains